Literature DB >> 30563995

Management of Chronic Hepatitis B: Knowledge and Practices of Physicians in Pakistan.

Qurat-Ul-Ain Hafeez1, Amna S Butt1, Furqaan Ahmed1.   

Abstract

BACKGROUND: In Pakistan, approximately 4.5 million people are afflicted with chronic hepatitis B (CHB). The compliance with hepatitis B virus (HBV) management guidelines is still unknown. This was the first study from Pakistan in which the knowledge and practices of treating physicians were compared with three standardized guidelines (Asia Pacific Association for the Study of the Liver (APASL) 2012/European Association for the Study of the Liver (EASL) 2012/American Association for the Study of Liver Diseases (AASLD) 2009).
METHODS: A cross-sectional study was conducted during 2014-2015 at four tertiary care teaching hospitals of Karachi, Pakistan. The study participants were internists, gastroenterologist, senior residents who were involved in the management of CHB patients. All participants were offered to fill the study questionnaire.
RESULTS: A total of 179 physicians (103 residents, 76 consultants) participated. Mean age of participant was 35 ± 9.3 years. Approximately one-third of them followed AASLD (27.3%) and EASL (24.0%) guidelines. Entecavir, tenofovir or Peg IFN ∞ 2a were considered as first line therapy by 43%, 38.5% and 30.2% respectively. However, 17.9% preferred entecavir with tenofovir for rescue therapy, 25.7% and 23.5% preferred tenofovir or entecavir as both first line and rescue therapy respectively. Serum HBV DNA, alanine transaminase levels were used to monitor during oral antivirals therapy by 45.3%. hepatocellular carcinoma screening was considered for all HBV cases by 51.4% using ultrasound (55.3%) and alfa fetoprotein (52.5%) every 6 months.Overall 40.2% participants had poor knowledge about indication of liver biopsy, treatment initiation and antiviral prophylaxis. Significant association was found between grades of knowledge and gender, age group, designation and specialty (P < 0.05). Younger physicians, consultants (age 25-40 years) and those who were practicing gastroenterology/hepatology were more likely to have higher knowledge scores in compliance with the guidelines as compared to others.
CONCLUSION: Our study highlighted the gaps in knowledge and practices in managing CHB patients according to guidelines. Efforts to improve knowledge, refresher courses and appropriate coordination between gastroenterologists and internal medicine physicians could enable management and follow-up of patients with CHB effectively.

Entities:  

Keywords:  AASLD, American Association for the Study of Liver Diseases; ADV, adefovir; APASL, Asia Pacific Association for the Study of the Liver; CHB, chronic hepatitis B; EASL, European Association for the Study of the Liver; ESLD, end stage liver disease; ETV, entecavir; HBIg, hepatitis B immunoglobulin; HCC, hepatocellular carcinoma; LAM, lamivudine; NAs, nucleoside/nucleotide analogs; PMDC, Pakistan Medical and Dental Council; Peg IFN, pegylated interferon; TDF, tenofovir; chronic hepatitis B; compliance; guidelines; knowledge; practices

Year:  2018        PMID: 30563995      PMCID: PMC6286432          DOI: 10.1016/j.jceh.2017.12.009

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  19 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

3.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

4.  Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?

Authors:  Joseph J Y Sung; Deepak Amarapurkar; Henry L Y Chan; Jun Cheng; Jia-Horng Kao; Kwang-Hyub Han; Teerha Piratvisuth
Journal:  Antivir Ther       Date:  2010

5.  Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand.

Authors:  Siwaporn Chainuvati; Jun Cheng; Jin Lin Hou; Chao Wei Hsu; Ji Dong Jia; Piyawat Komolmit; So Young Kwon; Chang Hong Lee; Hong Li; Ying Li; Chun Jen Liu; Boon Leong Neo; Cheng Yuan Peng; Tawesak Tanwandee; Suchat Wongcharatrawee; Jaw Ching Wu; Ming Lung Yu; Xin Xin Zhang
Journal:  Hepatol Int       Date:  2009-06-24       Impact factor: 6.047

6.  Management of hepatitis B: a longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines.

Authors:  Paul Marotta; Kurt Lucas
Journal:  Can J Gastroenterol       Date:  2010-09       Impact factor: 3.522

Review 7.  Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

Authors:  Gloria Woo; George Tomlinson; Yasunori Nishikawa; Matthew Kowgier; Morris Sherman; David K H Wong; Ba Pham; Wendy J Ungar; Thomas R Einarson; E Jenny Heathcote; Murray Krahn
Journal:  Gastroenterology       Date:  2010-06-20       Impact factor: 22.682

8.  Current trends in chronic hepatitis B management: results of a questionnaire.

Authors:  Iñigo Les; Rita García-Martínez; Juan Córdoba; Manuel Quintana; Rafael Esteban; María Buti
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 2.566

9.  Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.

Authors:  Timothy Juday; Hong Tang; Melissa Harris; Annette Z Powers; Edward Kim; George J Hanna
Journal:  J Gen Intern Med       Date:  2010-10-27       Impact factor: 5.128

10.  Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers.

Authors:  Mandana Khalili; Jennifer Guy; Albert Yu; Alexander Li; Nadia Diamond-Smith; Susan Stewart; Moon Chen; Tung Nguyen
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.